Genmab Announces Multiple Abstracts To Be Presented At 2023 ASCO Meeting
Portfolio Pulse from Benzinga Newsdesk
Genmab announced multiple abstracts to be presented at the 2023 ASCO Meeting, highlighting epcoritamab-bysp in combination with rituximab-lenalidomide (R2) in high-risk follicular lymphoma and epcoritamab in lymphoma across multiple lines of therapy and histologies.
May 25, 2023 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genmab's presentations at the 2023 ASCO Meeting may increase investor interest in the company's epcoritamab-based lymphoma treatments.
Genmab's presentations at the 2023 ASCO Meeting will showcase the company's epcoritamab-based lymphoma treatments, which may attract investor interest and potentially lead to increased demand for the company's stock. The presentations highlight the company's commitment to addressing high unmet needs in lymphoma treatment, which could positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100